why does GIP agonism seem to reduce nausea rather than add to it
Asking properly rather than in a comment on somebody else’s thread: why does GIP agonism seem to reduce nausea rather than add to it.
Why mechanism talk keeps misleading people, including me.
A mechanism tells you a direction. It does not tell you a magnitude, a timescale, or whether the pathway is operative at the exposures involved. "Receptor X is expressed in tissue Y" is a fact; "therefore effect Z in a person" is a hypothesis with several missing steps.
The corrective is boring and it works: ask whether the evidence is preclinical or human, ask what exposure was used, and read the limitations section before the abstract. Most of the confidently wrong posts on this board — several of them mine — skipped all three.
GLP-1 receptor agonism acts both peripherally — insulin secretion in a glucose-dependent way, slowed gastric emptying — and centrally, on appetite regulation. The central component is the better explanation for sustained intake reduction.
The incretin effect is the observation that oral glucose provokes a larger insulin response than intravenous glucose at matched glycaemia, and the difference is mediated by gut hormones. That is the foundation the whole class sits on.
Ask me anything specific. Anything general I will probably get wrong.
best — the order this archive was captured in
Long half-life in this class comes from structural modification that promotes albumin binding and resists enzymatic degradation. Weekly dosing is a consequence of the molecule, not a convenience decision.
Went looking for human data on a mechanism everybody here asserts. Found preclinical work and one small study. That was clarifying.
Disagree. That is a preclinical finding in a rodent model and you are stating it as human pharmacology.
Glucose-dependent insulin secretion is why hypoglycaemia risk is low as monotherapy: the effect scales with glycaemia rather than acting unconditionally.
Right — mechanism gives you a direction. It never gives you an effect size and people use it as though it does.
What does the discussion section say about the limitation you are glossing?
Yes. The discussion section is where the authors say what they actually think, and almost nobody here reads it.
Spent an evening on the receptor distribution literature and the side-effect map suddenly stopped looking random.
a mechanism you can state is not a mechanism you have demonstrated
GIP receptor biology is genuinely unsettled — there is a live argument about agonism versus antagonism at the receptor — and the clinical results are robust regardless, which is an uncomfortable and interesting position.
gastric emptying slows, it does not stop
Retitled to distinguish preclinical from clinical, which the original ran together.
That study was in a rodent model. Worth stating, since the thread has been reading it as human data.
Read the primary paper after arguing about the summary for a fortnight. The discussion section said almost the opposite of what the thread had concluded.
mechanism explains a direction, not a magnitude
Which receptor arm are you attributing that to?
Small fix — it slows gastric emptying, it does not halt it, and the distinction matters for the mechanism you are proposing.
What was the exposure in that experiment relative to therapeutic?
Do you have the paper, or a summary of it?
receptor agonism is not the same as receptor activation in every tissue
Correction: that is glucose-dependent insulin secretion, which is why hypoglycaemia risk is low as monotherapy. Not the same claim as you made.
Does the effect persist with continued dosing or does tolerance develop?
Receptor expression in a tissue is necessary but not sufficient for an effect. You also need the agonist to reach it at relevant exposure, and that is where a lot of confident mechanism talk falls down.
- 1Glucose-dependent insulin secretion is why hypoglycaemia risk is low as…6 comments in this branch · started by u/annika_fonseca